Trevena is a biopharmaceutical company. Co.'s primary product, OLINVYK (oliceridine) injection, is an opioid agonist for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Co.'s product candidates include: TRV250, which is a G-protein biased delta-opioid receptor agonist as a compound with a mechanism for the treatment of acute migraine; TRV045, which is Co.'s sphingosine-1-phosphate receptor modulator that may provide a non-opioid approach to managing chronic pain; as well as TRV734, a new chemical entity targeting the same mechanism of action at the mu opioid receptor as OLINVYK. The TRVN stock yearly return is shown above.
The yearly return on the TRVN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TRVN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|